New drug combo shows promise in shrinking lung tumors before surgery
NCT ID NCT07550920
First seen Apr 30, 2026 · Last updated Jun 21, 2026 · Updated 5 times
Summary
This phase 2 trial tests whether adding the drug retlirafusp alfa to standard chemotherapy before surgery can improve outcomes for people with stage II-III non-small cell lung cancer. Eighteen participants will receive the drug combo, then undergo surgery, followed by a year of maintenance therapy. The study looks at how many patients have no cancer cells left after treatment and how safe the approach is.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Retlirafusp alfa (a drug) combined with single-agent chemotherapy (nab-paclitaxel or pemetrexed)
What this could lead to
If successful, this could offer a new treatment option to shrink tumors before surgery and improve long-term outcomes for people with early-stage lung cancer.
What could go wrong
This is a small, early-phase trial with only 18 participants, so results may not apply to everyone. The drug combination may cause side effects or not work better than standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.